|
Patent landscape, scope, and claims: |
US Patent 11,186,584: What Is Claimed and How the Patent Landscape Works
What exactly does US 11,186,584 claim?
US 11,186,584 is a focused solid-state and formulation/process patent around a single chemical entity:
Compound 1: (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (freebase form).
The patent is built around two pillars:
- Crystalline freebase polymorph/solid forms defined by X-ray powder diffraction (XRPD) peak sets (claims 1, 3, 4, 5, 6, 7, 8).
- Conversion of that crystalline freebase into an amorphous freebase during pharmaceutical composition preparation, again controlled by XRPD identity and conversion yield thresholds (claims 2, 9–23).
Claim 1: Crystalline freebase defined by XRPD (three tight peak sets)
Claim 1 is a Markush-style selection of crystalline freebase Compound 1, where the XRPD pattern must match one of three sets (all measured at about 25° C. with Cu Kα1 monochromatic radiation):
- 1(a) peaks at 15.5±0.2, 17.0±0.2, 21.7±0.2 degrees 2θ
- 1(b) peaks at 3.1±0.2, 9.4±0.2, 21.1±0.2 degrees 2θ
- 1(c) peaks at 3.1±0.2, 9.3±0.2, 20.8±0.2 degrees 2θ
This claim reads like an identity claim: infringement hinges on proving the accused material has the asserted XRPD peak pattern(s) within the tight windows.
Claim 3–4: Narrower XRPD definition and “extra peaks”
- Claim 3 narrows the crystalline form to the (3.1, 9.4, 21.1) peak set.
- Claim 4 adds a further defining feature: at least one additional XRPD peak at one of:
- 5.4±0.2
- 12.1±0.2
- 19.1±0.2
The “at least one additional peak” language matters: it creates a second layer for distinguishing specific crystal forms from close neighbors.
Claim 5: Solvate-specific hook
- Claim 5 adds that the (3.1, 9.4, 21.1) crystalline form is an isopropyl acetate/water solvate.
Claim 6–7: Alternate crystalline XRPD set and extra peaks
- Claim 6 uses the (3.1, 9.3, 20.8) peak set.
- Claim 7 adds at least one additional peak from:
Claim 8: Hydrate-specific hook
- Claim 8 states the (3.1, 9.3, 20.8) crystalline form is a hydrate.
What is the core process claim and how broad is it?
Claim 2: Crystalline-to-amorphous conversion during composition prep
Claim 2 is the central operational claim. It claims a process for preparing a pharmaceutical composition comprising amorphous freebase Compound 1 by:
- Contacting a crystalline freebase Compound 1 with a pharmaceutically acceptable carrier
- Where the crystalline freebase is selected from two XRPD-defined crystalline sets:
- 2(a) peaks 3.1±0.2, 9.4±0.2, 21.1±0.2
- 2(b) peaks 3.1±0.2, 9.3±0.2, 20.8±0.2
- And the crystalline freebase is converted into amorphous freebase.
This is a process-by-structure claim: you need to match the starting crystalline XRPD identity, then show the process yields amorphous freebase in the composition.
Claim 9–10: Contacting method and carrier constraint
- Claim 9 limits contacting to dispersing the crystalline freebase in the carrier.
- Claim 10 limits carrier to a hydrophilic polymer.
This reduces scope vs claim 2 but still targets a common manufacturing path for solid oral dosage and controlled-release compositions where amorphization is induced or stabilized.
Claims 11–12: Conversion yield thresholds
- Claim 11: at least 80% by weight converted into amorphous freebase.
- Claim 12: at least 98% by weight converted into amorphous freebase.
These are high evidentiary thresholds; they function as hard guardrails for what counts as “conversion” in infringement.
How does the patent create multiple infringement entry points?
The claim set builds overlapping coverage so that different evidence sets can establish infringement:
A. XRPD identity claims (product-form, crystalline state)
- Claim 1: crystalline freebase defined by three peak-pattern options (including the “15.5/17.0/21.7” set).
- Claims 3–4: more specific XRPD and extra peaks.
- Claims 5, 8: solvates/hydrate tied to specific XRPD peak sets.
B. Process claims (manufacturing, crystalline-to-amorphous conversion)
- Claim 2: conversion during contact with a carrier (XRPD selection of two crystalline sets).
- Claim 9–10: dispersing and hydrophilic polymer.
- Claims 11–12: conversion extent cutoffs.
C. Dependent process claims (same process, tighter starting material identity)
Claims 13–18 and 15–18 replicate claim 2’s XRPD selection and then add:
- additional peak presence (claims 14, 17)
- solvate or hydrate character (claims 15, 18)
- XRPD set choice (claims 16–17)
This structure matters for landscape: if a competitor uses a different starting crystal that does not match those XRPD sets, they may avoid some claims. If they do use one of those crystals but tune conversion %, carrier, or dispersion method, dependent claims become the pressure points.
Where is the legal “scope” concentrated: crystalline definition vs amorphous outcome?
The claim language pushes infringement analysis toward two technical proofs:
-
What the starting crystalline freebase is
Controlled by XRPD peaks with ±0.2 degree 2θ tolerances at about 25° C. using Cu Kα1.
-
What the process does to the solid state
Requires conversion to amorphous freebase and, in dependent claims, conversion by weight of at least 80% or 98%.
That division creates a two-stage infringement model:
- Even if the process produces amorphous material, it still must start from one of the XRPD-defined crystalline forms listed in claim 2 (and dependent versions).
- Conversely, even if the starting crystal is correct, if conversion is below the claimed threshold (in dependent claims) or if carrier/method differ (claims 9–10), narrower claims may not be met.
How does the solvate/hydrate language affect landscape risk?
Claims 5 and 8 tie specific solid-state variants to the XRPD-defined crystalline sets:
- isopropyl acetate/water solvate for the (3.1, 9.4, 21.1) set
- hydrate for the (3.1, 9.3, 20.8) set
From a landscape standpoint, this is a classic “extra hook” that can catch competitors who identify their solid as a hydrate/solvate in addition to XRPD identity. It also gives two separate technical routes for proving infringement:
- XRPD peak sets alone (claims 1–4, 6–7, 13–14, 16–17)
- XRPD plus solvate/hydrate classification (claims 5, 8, 15, 18)
What does claim dependency imply about enforceability posture?
The independent claim is claim 1 and claim 2, with product-form coverage in claim 1 and manufacturing-conversion coverage in claim 2.
Dependent claims then:
- constrain the starting material identity (XRPD subsets and additional peaks),
- constrain how the carrier is used (hydrophilic polymer; dispersing),
- constrain the outcome (80% or 98% conversion).
This pattern typically supports a litigation/enforcement strategy where:
- broadest independent claims anchor infringement positions,
- dependent claims provide fallback theories if the strongest technical matches fail under evidence testing.
Detailed claim map (by XRPD signature and solid-state outcome)
XRPD-defined crystalline forms in the claim set
All peaks are degrees 2θ (Cu Kα1), ~25° C., with ±0.2° tolerance.
| Claim group |
XRPD peak set (required) |
Additional defining layer |
Solid-state label in dependent claims |
| Claim 1(a) |
15.5±0.2 / 17.0±0.2 / 21.7±0.2 |
None stated |
None |
| Claim 1(b), 3, 4, 2(a), 13, 14, 15 |
3.1±0.2 / 9.4±0.2 / 21.1±0.2 |
At least one extra peak 5.4±0.2 or 12.1±0.2 or 19.1±0.2 |
isopropyl acetate/water solvate (claims 5, 15) |
| Claim 1(c), 6, 7, 2(b), 16, 17, 18 |
3.1±0.2 / 9.3±0.2 / 20.8±0.2 |
At least one extra peak 12.0±0.2 or 25.0±0.2 |
hydrate (claims 8, 18) |
Crystalline-to-amorphous conversion claims
| Claim |
Process scope |
Carrier/method constraints |
Conversion threshold |
| Claim 2 |
Make a pharmaceutical composition comprising amorphous freebase by contacting crystalline freebase with a pharmaceutically acceptable carrier |
No specific method; starting crystal must match XRPD sets (2(a) or 2(b)) |
None in claim 2 |
| Claim 9 |
Adds contacting step method |
Crystalline dispersed in carrier |
None |
| Claim 10 |
Adds carrier identity |
Carrier is a hydrophilic polymer |
None |
| Claim 11 |
Same process |
Same constraints as claim 2 plus those not dependent-filtered |
≥80% by weight converted |
| Claim 12 |
Same process |
Same constraints as claim 2 plus those not dependent-filtered |
≥98% by weight converted |
Patent landscape implications: what competitors must avoid (claim-logic view)
This patent does not claim the compound broadly in the abstract; it claims specific solid forms and a specific solid-state conversion process tied to XRPD-defined starting crystals.
Most direct infringement risk
- Selling or using crystalline freebase Compound 1 whose XRPD matches (3.1/9.4/21.1) or (3.1/9.3/20.8), or the (15.5/17.0/21.7) set where claim 1 applies.
- Manufacturing dosage forms or intermediates where the disclosed process is followed:
- start from one of the listed crystalline XRPD forms,
- contact with a pharmaceutically acceptable carrier (especially hydrophilic polymer),
- convert to amorphous freebase in the stated yield range if dependent claims are at issue.
Typical design-around levers (based on claim language)
- Use a starting crystalline form of Compound 1 that does not match the XRPD peak sets listed in claim 2 (for process claims), or does not match the XRPD options in claim 1 (for crystalline product claims).
- If manufacturing aims at amorphous freebase, adjust the process to fall outside dependent claim constraints:
- not using hydrophilic polymer (claim 10),
- not using dispersing (claim 9),
- converting below 80% or 98% thresholds (claims 11–12),
- or producing amorphous material that does not meet the amorphous characterization standard used by the patent (not provided in the text supplied, but amorphous freebase is required by the claim).
Key Takeaways
- US 11,186,584 targets Compound 1 in specific crystalline XRPD-defined forms and a specific manufacturing pathway that converts those crystals into amorphous freebase during pharmaceutical composition preparation.
- Claims 1 and 2 are the core hooks:
- Claim 1: crystalline freebase identity is set by three XRPD peak options.
- Claim 2: process infringement depends on using one of two XRPD-defined crystalline starting forms, contacting with a carrier, and achieving conversion to amorphous freebase.
- Dependent claims sharpen risk for competitors using:
- hydrophilic polymer carriers,
- dispersing as the contacting method,
- high conversion yields of ≥80% or ≥98%.
- Solvate/hydrate dependencies add evidentiary paths:
- isopropyl acetate/water solvate attaches to the (3.1/9.4/21.1) crystalline set.
- hydrate attaches to the (3.1/9.3/20.8) crystalline set.
FAQs
1) What XRPD peaks define the crystalline forms most tied to the process claim?
Claim 2 limits the starting crystalline freebase to two XRPD sets:
- 3.1±0.2 / 9.4±0.2 / 21.1±0.2
- 3.1±0.2 / 9.3±0.2 / 20.8±0.2
(All at about 25°C with Cu Kα1, per the claim language.)
2) Does the patent require a specific dosage form?
No dosage form is specified in the provided claim text. It requires preparation of a pharmaceutical composition that comprises amorphous freebase (claims 2, 19).
3) Are conversion thresholds only in dependent claims?
Yes. Claim 11 sets ≥80% by weight conversion; claim 12 sets ≥98% by weight conversion. The independent process claim 2 does not state a numeric threshold in the provided excerpt.
4) Do solvate/hydrate labels expand or narrow claim scope?
They narrow the claim by adding a solid-state identity characteristic:
- Claim 5 and 15 require isopropyl acetate/water solvate for the (3.1/9.4/21.1) crystal set.
- Claim 8 and 18 require a hydrate for the (3.1/9.3/20.8) crystal set.
5) What is the main enforcement target: crystalline material or amorphization process?
Both. The patent covers:
- crystalline freebase identity (claim 1 and dependents),
- and the conversion process during pharmaceutical composition preparation (claim 2 and dependents).
References
[1] US Patent 11,186,584 (claims as provided by user prompt).
More… ↓
⤷ Start Trial
|
